8-K: Korro Bio CFO Resigns; CEO Aiyar Appointed Interim CFO

Korro Bio announced the resignation of Chief Financial Officer Vineet Agarwal, effective October 17, 2025, with President and CEO Ram Aiyar stepping in as interim Chief Financial Officer.

Summary

• Vineet Agarwal announced his intention to resign from his position as Chief Financial Officer of Korro Bio, Inc., effective October 17, 2025, to pursue another opportunity.
• Mr. Agarwal's departure is amicable and not related to any disagreement regarding the management, operations, policies, or practices of Korro Bio.
• To ensure a smooth transition, Mr. Agarwal will be available to serve as an advisor for 30 days following his resignation, compensated at $300 per hour for up to 10 hours per week.
• In connection with his resignation, Korro Bio and Mr. Agarwal entered into a Separation Agreement, effective October 7, 2025.
• The Separation Agreement provides for separation benefits including nine months of his Base Salary ($352,500) paid in installments, and a prorated FY 2025 Target Bonus ($149,400) paid as a lump sum.
• Korro Bio will also pay monthly COBRA premiums for up to nine months, or until Mr. Agarwal becomes eligible for another group medical plan.
• The post-termination exercise period for Mr. Agarwal's vested stock options as of October 17, 2025, has been extended through March 31, 2027.
• Dr. Ram Aiyar, the current President and Chief Executive Officer, has been appointed to serve as Korro Bio's interim Chief Financial Officer and principal financial officer, effective October 17, 2025, in addition to his existing duties.
• Dr. Aiyar will not receive any additional compensation for his interim CFO appointment.

Sentiment

Score: 6

Explanation: While the departure of a CFO is a significant executive change, the company has outlined a clear, amicable transition plan, including an interim appointment and advisory period, mitigating immediate concerns. The CEO taking on the interim role without additional compensation is also a positive signal of commitment and cost management.

Positives

• The departure of the CFO is amicable and not due to disagreements, indicating a professional separation.
• A clear transition plan is in place, with Mr. Agarwal agreeing to serve as an advisor for 30 days to ensure continuity.
• The President and CEO, Dr. Ram Aiyar, has been appointed as interim CFO, providing immediate leadership stability in the finance function.
• Dr. Aiyar will not receive additional compensation for the interim CFO role, which is a cost-saving measure for the company.

Negatives

• The departure of a Chief Financial Officer, a key executive, introduces an element of uncertainty and requires the company to find a permanent replacement.
• The company will incur significant separation benefit costs, including $352,500 in base salary and $149,400 in prorated bonus, plus COBRA payments and advisory fees.

Risks

• Potential disruption to financial operations and investor relations during the search for a permanent CFO.
• Risk of Mr. Agarwal breaching post-employment obligations, including non-competition, non-solicitation, and confidentiality clauses, which could lead to legal action and harm the company.
• The non-competition clause for 'RNA editing for therapeutic applications' in the 'Restricted Territory' may be challenging to enforce or could be contested.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on the executive transition.

Management Comments

• The board of directors of Korro, or the Board, and Korro are incredibly thankful to Mr. Agarwal for his long-standing service at Korro.

Industry Context

This announcement is an internal corporate governance event and does not directly relate to broader industry trends or competitive landscape. It reflects a standard executive transition within a biotechnology company.

Comparison to Industry Standards

• The separation terms, including severance pay, prorated bonus, COBRA benefits, and extended stock option exercise period, are generally consistent with industry standards for amicable executive departures in the biotechnology sector.
• The inclusion of a one-year post-employment non-competition agreement, specifically for 'RNA editing for therapeutic applications,' is a common protective measure for companies in specialized fields.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: May experience short-term uncertainty due to the CFO transition, but the structured and amicable nature of the departure, coupled with an interim appointment, aims to minimize disruption.
• Employees: The departure of a senior executive could impact morale, but the clear communication and transition plan may help maintain stability.
• Creditors/Suppliers: Unlikely to be significantly impacted by this executive change, given the interim leadership and continuity plan.

Next Steps

• Korro Bio will commence a search for a permanent Chief Financial Officer.
• Mr. Agarwal will provide advisory services for 30 days post-resignation to assist with the transition.

Key Dates

Recommendation

The departure of a key executive like the CFO introduces some uncertainty. However, the amicable nature of the resignation, the clear transition plan, and the appointment of the CEO as interim CFO without additional compensation suggest a well-managed process. This event does not fundamentally alter the company's strategic direction or financial health as presented in this filing, thus a 'hold' recommendation is appropriate while awaiting further updates on a permanent replacement and business performance.

Keywords

Korro Bio, KRRO, CFO resignation, interim CFO, executive change, financial officer, corporate governance, SEC filing, 8-K, biotechnology, RNA editing